WallStSmart

Northrop Grumman Corporation (NOC)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Northrop Grumman Corporation generates 1024% more annual revenue ($42.37B vs $3.77B). WAT leads profitability with a 11.9% profit margin vs 10.8%. WAT appears more attractively valued with a PEG of 1.52. NOC earns a higher WallStSmart Score of 63/100 (C+).

NOC

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: 1.96

WAT

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 3.3Quality: 6.8
Piotroski: 4/9Altman Z: 4.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NOCSignificantly Overvalued (-60.9%)

Margin of Safety

-60.9%

Fair Value

$421.87

Current Price

$549.52

$127.65 premium

UndervaluedFair: $421.87Overvalued
WATSignificantly Overvalued (-63.1%)

Margin of Safety

-63.1%

Fair Value

$201.83

Current Price

$355.13

$153.30 premium

UndervaluedFair: $201.83Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NOC4 strengths · Avg: 9.0/10
EPS GrowthGrowth
84.9%10/10

Earnings expanding 84.9% YoY

Market CapQuality
$78.44B9/10

Large-cap with strong market position

Return on EquityProfitability
28.5%9/10

Every $100 of equity generates 29 in profit

P/E RatioValuation
17.3x8/10

Attractively priced relative to earnings

WAT2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
91.5%10/10

Revenue surging 91.5% year-over-year

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

Areas to Watch

NOC4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WAT4 concerns · Avg: 3.3/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

P/E RatioValuation
44.6x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : NOC

The strongest argument for NOC centers on EPS Growth, Market Cap, Return on Equity.

Bull Case : WAT

The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.5% demonstrates continued momentum.

Bear Case : NOC

The primary concerns for NOC are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : WAT

The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 44.6x leaves little room for execution misses.

Key Dynamics to Monitor

NOC profiles as a value stock while WAT is a growth play — different risk/reward profiles.

WAT carries more volatility with a beta of 1.14 — expect wider price swings.

WAT is growing revenue faster at 91.5% — sustainability is the question.

WAT generates stronger free cash flow (-42M), providing more financial flexibility.

Bottom Line

NOC scores higher overall (63/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Northrop Grumman Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Northrop Grumman Corporation (NYSE: NOC) is an American multinational aerospace and defense technology company.

Visit Website →

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?